CD112R (PVRIG), Fc-Fusion, Avi-Tag, Biotin-Labeled (Human) HiP™ Recombinant

Only %1 left
Catalog #
79270
As low as $295 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human CD112R, also known as PVRIG (Poliovirus receptor-related Immunoglobulin domain-containing protein), encompassing amino acids 41-172. This construct containsan C-terminal Human IgG1, Fc region followed by an Avi-Tag™. The recombinant protein was affinity purified. HiP™ indicates a high purity protein with ≥90% purity as measured by gel filtration.

Synonyms
Poliovirus Receptor-related Immunoglobulin Domain-containing Protein, Transmembrane Protein PVRIG
Product Info
Storage and Usage
Citations
Species
Human
Construct
CD112R (41-172-Fc-Avi)-(Biotin)
Host Species/Expression System
HEK293
Purity

≥90%

Format
Aqueous buffer solution
Formulation
8 mM Phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol.
MW
42 kDa
Amino Acids
41-172
Aggregation
<10%
Genbank #
NM_024070
UniProt #
Q6DKI7
Tag(s)
C-terminal Fc-Fusion- Avi-Tag
Label

This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation confirmed to be ≥90%.

For more information on enzymatic biotinylation, please see our Tech Note

Background

CD112R (Poliovirus receptor-related immunoglobulin domain containing, PVRIG) is the receptor for CD112 (Poliovirus receptor-related 2, PVRL2) found on antigen-presenting cells and tumor cells. CD112R is present in NK and T cells, particularly CD8+ T cells. Elevated levels of this receptor are observed in NK, CD8+, and CD4+ T cells in patients with cancer of the kidney, ovary, lung, prostate, and endometrium, and in acute myeloid leukemia (AML). CD112-CD112R complex acts as a positive immune checkpoint, boosting human T cell response and serving as a promising therapeutic target in oncology. TIGIT (T cell immunoreceptor with Ig and ITIM domains) and CD226 (also known as DNAM-1, DNAX Accessory Molecule-1) also bind CD112. Developing inhibitors to hinder CD112R-CD112 interaction alone or combined with blocking TIGIT-CD155/CD112 interaction holds promise for cancer therapy.

References
1. Bottino, C., et al., J. Exp. Med. 2003; 198(4): 557-567.

2. Pende, D., et al., Blood. 2005; 105(5): 2066-2073